NYXH logo

NYXOAH SA

NYXHNASDAQ
🏆 #3939 by market capEarnings Nov 5US Equity
$1.37▼ $0.19 (−13.84%)
🌙 After hours$1.38▲ 0.73%Regular close · extended-hours price shown
🔔
Track NYXH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 13.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$137M
Small Cap
📈Revenue Growth (YoY)
+121.6%
High Growth
📊Gross Margin
51.3%
Healthy
💵FCF Margin
-326.1%
Thin
⚖️P/S Ratio
5.3x
Fair
Otter Score
76
Good
No chart data available for NYXH.

Trading Snapshot

Day Range
$1.36 – $1.39
52-Week Range
$1.26 – $6.88
Volume
$3.26B
Avg Volume
$3.31B
Shares Outstanding
100.1M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$8M
P/E Ratio
-0.6
P/S Ratio
5.3x
EPS (TTM)
$-1.73
Dividend Yield
0.00%
Dilution (1yr)
+8.3%

Why Investors Own NYXH

  • ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NYXH logo

NYXOAH SA

NYXH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10M▲ +121.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.1%▼ −3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$83M▲ +41.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$68M▲ +23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.1M▲ +8.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$10M▼ −$22M YoY
StockOtter · stockotter.space

About NYXOAH SA

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$1.41
▲ +3.0% Upside
High Target$1.74
Low Target$1.11
Based on 21 analysts

Latest News & Updates

GlobeNewsWire·1d ago

Nyxoah Appoints Liam Kelly as Chief Executive Officer

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30

GlobeNewsWire·8d ago

Nyxoah Announces Chief Financial Officer Transition

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah's President International and former CFO, to serve as interim CFO Company reaffirms full year 2026 financia

Zacks Investment Research·21d ago

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

Globe News Wire·22d ago

Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®

Nyxoah Annonce l'Implantation du Premier Patient dans BREATHE, l'Étude Post-Approbation Américaine du Système Genio BREATHE prévoit d'implanter jusqu'à 229 patients dans jusqu'à 25 centres américains, suivis pendant une

GlobeNewsWire·22d ago

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System

Seeking Alpha·Aug 5

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript